SEARCH

SEARCH BY CITATION

References

  • 1
    Klein HG. The prospects for red-cell substitutes. N Engl J Med 2000; 342: 16668.
  • 2
    Chang TMS. Red blood cell substitutes. Best Practice Res Clin Haematol 2000; 13: 65168.
  • 3
    Winslow RM. Blood substitutes. Adv Drug Deliv Rev 2000; 40: 13142.
  • 4
    Chang TMS. Oxygen carriers. Curr Opinion Invest Drugs 2002; 3: 118790.
  • 5
    Squires JE. Artificial blood. Science 2002; 8: 10025.
  • 6
    Chang TMS. Semipermeable microcapsules. Science 1964; 146: 5245.
  • 7
    Chang TMS. Artificial Cells. Monograph. Springfield, IL: Charles C Thomas, 1972 (full text available for free online viewing at http://www.artcell.mcgill.ca).
  • 8
    Chang TMS. Stabilization of enzyme by microencapsulation with a concentrated protein solution or by crosslinking with glutaraldehyde. Biochem Biophys Res Com 1971; 44: 15313.
  • 9
    Savitsky JP, Doozi J, Black J, Arnold JD. A clinical safety trial of stroma free hemoglobin. Clin Pharm Ther 1978; 23: 73.
  • 10
    Chang TMS. Blood Substitutes: Principles, Methods, Products and Clinical Trials, Vol. 1. Basel: Karger, 1997 (full text available for free online viewing at http://www.artcell.mcgill.ca).
  • 11
    Gould SA, Sehgal LR, Sehgal HL, DeWoskin R, Moss GS. The clinical development of human polymerized hemoglobin. In: ChangTMS, ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials, Vol. 2. Basel: Karger, 1998; 1228.
  • 12
    Gould SA, Moore EE, Hoyt DB et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998; 187: 11320.
  • 13
    Pearce LB, Gawryl MS. Overview of preclinical and clinical efficacy of Biopure's HBOCs. In: ChangTMS, ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials, Vol. 2. Basel: Karger, 1988; 8298.
  • 14
    Sprung J, Kindscher JD, Wahr JA et al . The use of bovine hemoglobin glutamer-250 (Hemopure) in surgical patients: results of a multicenter, randomized, single-blinded trial. Anesth Analg 2002; 94: 799808.
  • 15
    Lok C. Blood product from cattle wins approval for use in humans. Nature 2001; 410: 855.
  • 16
    Adamson JG, Moore C, Hemolink TM. An o-Raffinose crosslinked hemoglobin-based oxygen carrier. In: ChangTMS, ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials, Vol. 2. Basel: Karger, 1998; 6279.
  • 17
    Carmichael FJ. Recent developments in hemoglobin-based oxygen carriers – an update on clinical trials. Transfus Apheresis Sci 2001; 24: 1721.
  • 18
    Wong JT. Rightshifted dextran hemoglobin as blood substitute. Biomaterials, Artificial Cells Artificial Organs 1988; 16: 23745.
  • 19
    Iwashita Y, Yabuki A, Yamaji K et al. A new resuscitation fluid ‘Stabilized hemoglobin’ preparation and characteristics. Biomaterials Artificial Cells Artificial Organs 1988; 16: 27180.
  • 20
    Shorr RG, Viau AT, Abuchowski A. Phase 1B safety evaluation of PEG hemoglobin as an adjuvant to radiation therapy in human cancer patients. Artficial Cells Blood Substitutes Immbolization Biotechnol Intern J 1996; 24: 407.
  • 21
    De Angelo J. Nitric oxide scavengers in the treatment of shock associated with systemic inflammatory response syndrome. Exp Opin Pharmacother 1999; 1: 1929.
  • 22
    KjellstromT (ed.). Proceedings of the Fourth International Symposium on Current Issues in Blood Substitute Research, 58 June 2002, Stockholm, Sweden.
  • 23
    Riess JG. In: ChangTMS, ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials, Vol. 2. Basel, Switzerland and Georgetown, Texas: Karger/Landes System, 1998; 10121.
  • 24
    Keipert PE. In: ChangTMS, ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials, Vol. 2. Basel, Switzerland and Georgetown, Texas: Karger/Landes System, 1998; 12756.
  • 25
    Bunn HF, Jandl JH. The renal handling of hemoglobin. Trans Assoc Am Physicians 1968; 81: 147.
  • 26
    Nelson DJ. Blood and HemAssistTM (DCLHb): potentially a complementary therapeutic team. In: ChangTMS, ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials, Vol. 2. Basel: Karger, 1998; 3957.
  • 27
    Hoffman SJ, Looker DL, Roehrich JM et al. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Proc Natl Acad Sci USA 1990; 87: 85215.
  • 28
    Freytag JW, Templeton D. OptroTM (recombinant human hemoglobin): a therapeutic for the delivery of oxygen and the restoration of blood volume in the treatment of acute blood loss in trauma and surgery. In: Red Cell Substitutes; Basic Principles and Clinical Application. RudolphAS, RabinoviciR, FeuersteinGZ, eds. New York: Marcel Dekker, Inc., 1997; 32534.
  • 29
    Doherty DH, Doyle MP, Curry SR et al. Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nature Biotechnology 1998; 16: 6726.
  • 30
    Alayash Al. Hemoglobin-based blood substitutes: oxygen carriers, pressor agents, or oxidants? Nature Biotechnology 1999; 17: 5459.
  • 31
    D'Agnillo F, Chang TMS. Polyhemoglobin–superoxide dismutase. Catalase as a blood substitute with antioxidant properties. Nature Biotechnology 1998; 16: 66771.
  • 32
    Chang TMS, D'Agnillo F, Razack S. A second generation hemoglobin based blood substitute with antioxidant activities. In: ChangTMS, ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials, Vol. 2. Basel: Karger/Texas: Landes, 1998; 17886.
  • 33
    D'Agnillo F, Chang TMS. Modified hemoglobin blood substitute from cross-linked hemoglobin–superoxide dismutase–catalase. US patent 1997; 5,606,025, pp. 1–6.
  • 34
    Powanda D, Chang TMS. Cross-linked polyhemoglobin–superoxide dismutase–catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia–reperfusion. Artificial Cells Blood Substitutes Immob. Biotechnol Intern J 2002; 30: 2542.
  • 35
    Smith ML, Bendek G, Dahlgren N, Rosen I, Wieloch T, Siesjo BK. Models for studying long-term recovery following forebrain ischemia in the rat. A 2-vessel occlusion model. Acta Neurol Scand 1984; 69: 385401.
  • 36
    Buehler PW, Mehendale S, Wang H et al. Resuscitative effects of polynitroxylated alpha-alpha-cross-linked hemoglobin following severe hemorrhage in the rat. Free Rad Biol Med 2000; 29: 76474.
  • 37
    Chang TMS. ‘Hemoglobin Corpuscles’ Report of a research project for Honours Physiology, Medical Library, McGill University 1957. Also reprinted as part of ‘30 anniversary in Artificial Red Blood Cells Research’. J Biomaterials Artificial Cells Artificial Organs 1988; 16: 19.
  • 38
    Chang TMS, Poznansky MJ. Semipermeable microcapsules containing catalase for enzyme replacement in acatalsaemic mice. Nature 1968; 218: 24245.
  • 39
    Poznansky MJ, Chang TMS. Comparison of the enzyme kinetics and immunological properties of catalase immobilized by microencapsulation and catalase in free solution for enzyme replacement. Biochim Biophys Acta 1974; 334: 10315.
  • 40
    Chang TMS, Prakash, S. Procedure for microencapsulation of enzymes, cells and genetically engineered microorganisms. Molecular Biotechnology 2001; 17: 24960.
  • 41
    Djordjevich L, Miller IF. Synthetic erythrocytes from lipid encapsulated hemoglobin. Exp Hematol 1980; 8: 584.
  • 42
    RudolphAS, RabinoviciR, FeuersteinGZ (eds). Red Blood Cell Substitutes: Basic Principles and Clinical Applications. New York: Marcel Dekker, Inc., 1997.
  • 43
    Philips WT, Klpper RW, Awasthi VD et al. Polyethylene glyco-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. J Pharm Exp Ther 1999; 288: 66570.
  • 44
    TsuchidaE (ed.). Blood Substitutes: Present and Future Perspectives. Amsterdam: Elservier, 1998.
  • 45
    Chang TMS. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioeng 1976; 1: 2532.
  • 46
    Yu WP, Chang TMS. Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: preparation and characterization. Artificial Cells Blood Substitutes Immobilization Biotechnol Intern J 1996; 24: 16984.
  • 47
    Chang TMS, Yu WP. Biodegradable polymer membrane containing hemoglobin for blood substitutes. US Patent 1997; 5670173.
  • 48
    Chang TMS, Yu WP. Nanoencapsulation of hemoglobin and rbc enzymes based on nanotechnology and biodegradable polymer. In: ChangTMS, ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials. Basel: Karger, 1998, Vol. 2, 21631.
  • 49
    Chang TMS, Yu WP. Biodegradable polymeric nanocapsules and uses thereof. US Provisional Patent 2001; No 60/316,001, pp. 1–17.
  • 50
    Chang TMS, Powanda D, Yu WP. Biodegradable polymeric nanocapsules and uses thereof. International Patent Application 2002; No PTC/CA02/01331, pp. 1–17.
  • 51
    Chang TMS, Yu YT, Grunwald J. Artificial cells immobilized multienzyme systems and cofactors. Enzyme Eng 1982; 6: 451561.
  • 52
    Binglan Yu, Chang TMS. Artificial cells for the removal of systemic tyrosine in rats. Proc Can Fed Biological Societies 45th Annual Meeting 2002; 76.